Strong demand for AstraZeneca's new drugs - especially those for cancer - drove a return to sales growth in the third quarter and the drugmaker said it now expected a period of sustained growth "for years to come".
from Earnings https://ift.tt/2SWfTrO
via IFTTT
No comments:
Post a Comment